Vibe Bioscience Ltd (VIBE) AI Stock Analysis

• Market Cap: C$863.76K
• Dividend Yield: N/A
• Average Volume (3M): 7.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.81
• Revenue Growth: 5.13%
• EPS Growth: 41.24%
• Country: CA
• Employees: 110
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 10,796,989
• 10 Day Avg. Volume: 10,251
• 30 Day Avg. Volume: 7,755
• PEG Ratio: -0.11
• Price to Book (P/B): 8.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.74
• Enterprise Value/Market Cap: 113.58
• Enterprise Value/Revenue: 1.94
• Enterprise Value/Gross Profit: 20.71
• Enterprise Value/Ebitda: -7.38
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

The overall stock score is heavily influenced by critical financial performance issues, including declining revenues, negative equity, and persistent losses. While technical analysis shows some positive momentum, it is not sufficient to offset the severe financial constraints. The stock's valuation is further weakened by its negative P/E ratio and lack of dividend yield.

Vibe Bioscience Ltd Business Overview & Revenue Model

Company Description

Vibe Bioscience Ltd (VIBE) is a cannabis company that engages in the cultivation, production, and retail of high-quality cannabis products. The company operates in the legal cannabis sector and focuses on providing a diverse range of products including flowers, edibles, concentrates, and other cannabis-infused products. VIBE is committed to delivering exceptional customer experiences through its retail dispensaries and online platforms, while adhering to regulatory compliance and sustainable practices.

How the Company Makes Money

Vibe Bioscience Ltd makes money primarily through the sale of cannabis products. Its key revenue streams include retail sales from its dispensaries and e-commerce platforms, where customers can purchase various cannabis products. The company also generates revenue from the cultivation and wholesale distribution of cannabis to other businesses. Additionally, VIBE may engage in strategic partnerships and branding initiatives to enhance its market presence and drive sales. The company's earnings are influenced by factors such as consumer demand, regulatory changes, and market competition within the cannabis industry.

Vibe Bioscience Ltd Financial Statement Overview

Summary

Vibe Bioscience Ltd is experiencing severe financial difficulties, with declining revenues, persistent losses, and negative equity. The balance sheet indicates significant solvency issues, and while cash flow has shown slight improvement, the overall financial condition remains precarious.

Income Statement

Vibe Bioscience Ltd has experienced a significant decline in revenue over the years, with a noticeable decrease from $24.2M in 2020 to $12.7M in 2024. Gross profit margins have also deteriorated, falling from 35.2% in 2020 to 37.2% in 2024. The company has consistently reported negative EBIT and net income, indicating ongoing operational challenges. The net profit margin has remained negative, highlighting profitability issues. Overall, the income statement reflects a company struggling with declining revenues and persistent losses.

Balance Sheet

The balance sheet of Vibe Bioscience Ltd presents significant concerns. The company's stockholders' equity turned negative in 2024, indicating potential solvency issues. The debt-to-equity ratio cannot be calculated due to negative equity, which is a red flag for leverage risk. The equity ratio has shifted from 55.1% in 2020 to negative in 2024, demonstrating weakened financial stability. Overall, the balance sheet shows a company with high liabilities and diminishing asset base, posing a risk to financial health.

Cash Flow

The cash flow statement shows some improvement in free cash flow in 2024, rising to $202,824 from a negative position in previous years. Operating cash flow turned positive in 2024, a positive sign, but the company still faces challenges with consistent negative free cash flow in past periods, indicating cash management issues. The operating cash flow to net income ratio is positive but low due to negative net income, suggesting operational cash generation struggles. Overall, the cash flow situation, while slightly improving, remains concerning.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.71M	14.15M	20.71M	29.29M	24.24M
Gross Profit	4.74M	5.17M	6.49M	8.42M	8.54M
EBITDA	-3.91M	-8.42M	-3.07M	-1.11M	3.05M
Net Income	-6.54M	-11.13M	-9.45M	-4.30M	728.55K
Balance Sheet
Total Assets	11.29M	16.28M	25.89M	32.90M	18.34M
Cash, Cash Equivalents and Short-Term Investments	1.06M	1.17M	4.55M	9.10M	2.41M
Total Debt	2.57M	2.89M	3.38M	2.83M	2.57M
Total Liabilities	16.51M	15.20M	13.63M	11.50M	8.23M
Stockholders Equity	-5.22M	1.08M	12.26M	21.39M	10.11M
Cash Flow
Free Cash Flow	202.82K	-2.78M	-3.71M	-7.20M	193.36K
Operating Cash Flow	233.74K	-2.71M	-1.97M	848.73K	724.34K
Investing Cash Flow	19.02K	-71.80K	-1.75M	-8.43M	362.35K
Financing Cash Flow	-360.37K	-595.55K	-699.14K	14.33M	-324.15K

Vibe Bioscience Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VIBE, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 47.03 is Neutral, neither overbought nor oversold. The STOCH value of 43.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VIBE.

Vibe Bioscience Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIBE	47 Neutral	C$863.76K	―	-201.37%	―	5.13%	41.24%
Sector *	46 Neutral	C$194.28M	-4.22	-8.60%	2.64%	13.54%	-1.44%
CNTR	25 Underperform	C$463.19K	―	39.03%	―	―	―

Vibe Bioscience Ltd Corporate Events

Vibe Growth Director to Reduce Stake with Share Sale

Mark Waldron, a director at Vibe Growth Corporation, has filed an Early Warning Report indicating his intention to sell 250,000 common shares of the company through the Canadian Securities Exchange. This move will reduce Waldron’s stake from 18.14% to 15.83% of the company’s outstanding shares. The sale is part of Waldron’s strategy to decrease his holdings and utilize the proceeds for other purposes, though he remains open to future transactions based on market conditions.